Abstract

COMPASS Pathways plc will report first-quarter 2026 results on May 13, 2026 Pre-Market, and this preview details consensus expectations for EPS, EBIT, and revenue alongside the quarter’s clinical, regulatory, financing, and operating milestones that could influence performance and investor sentiment.

Market Forecast

Consensus points to a pre-revenue quarter: total revenue is estimated at 0.00 million US dollars, flat year over year at 0%; EBIT is forecast at a loss of 47.06 million US dollars, implying a 6.84% year-over-year deterioration; and EPS is projected at -0.38, which indicates a 19.19% year-over-year improvement. Forecasts do not include gross margin or net profit margin, and net margin is not applicable given no revenue.

The quarter’s operational spotlight centers on the COMP360 program, including regulatory progress under a rolling review for a planned new drug application and continued execution on commercialization groundwork in care delivery settings. The most promising near-term value driver remains COMP360 for treatment-resistant depression, which currently generates 0.00 million US dollars in revenue, unchanged year over year at 0%.

Last Quarter Review

In the fourth quarter of 2025, COMPASS Pathways plc reported revenue of 0.00 million US dollars; gross profit margin was not disclosed; GAAP net loss attributable to the parent company was 93.88 million US dollars; net profit margin is not applicable given zero revenue; and reported EPS was -1.00, a year-over-year change of -58.73%.

A key quarterly development was the EPS miss versus consensus by 0.63, alongside an EBIT loss of 45.95 million US dollars that reflected continued investment in late-stage clinical and pre-commercial activities. With the business still pre-commercial, operating highlights concentrated on advancing the COMP360 program and regulatory preparations; segment revenue remained 0.00 million US dollars, flat year over year at 0%.

Current Quarter Outlook

Main business: COMP360 for treatment-resistant depression

The quarter is expected to revolve around advancing the regulatory path for COMP360, where a rolling review for the new drug application has been granted, enabling submission of completed sections ahead of the full filing. Recent positive clinical news—specifically, a second Phase 3 trial achieving its primary endpoint on February 18, 2026—provides important clinical de-risking for the core program and shapes investor expectations heading into the update. Management’s operational focus this quarter likely remains on regulatory filing logistics, chemistry-manufacturing-controls readiness, and clinical package consolidation, all of which are typical steps in the run-up to a filing under rolling review.

With consensus assuming no product revenue, attention will be on expense cadence and execution levers rather than top-line variability. The EBIT loss is expected to widen modestly year over year to 47.06 million US dollars, primarily reflecting the mix of regulatory and pre-commercial investments, while the EPS estimate of -0.38 suggests year-over-year improvement due to share count effects and operating discipline. Against that backdrop, milestone timing, clarity on what portions of the dossier have been submitted under the rolling review, and any additional clinical dataset updates are poised to be the main near-term stock drivers within the business.

Largest growth opportunity: COMP360 TRD commercialization pathway

The commercialization pathway for COMP360 is the central source of future growth optionality, even though revenue remains 0.00 million US dollars this quarter with flat year-over-year comparison at 0%. The collaboration announced on April 21, 2026 with Osmind is designed to detail real-world clinic workflows, infrastructure needs, and quality standards for delivering the investigational therapy at scale, and it provides a tangible step toward operationalizing delivery in community and specialty settings. Establishing consistent clinical protocols, data capture, and safety monitoring in outpatient environments is an important precursor to potential launch readiness, particularly for a therapy that involves coordinated care delivery.

This quarter, investors will look for signals that the necessary building blocks—therapy-site readiness, therapist training frameworks, patient selection criteria, and post-treatment monitoring templates—are proceeding on timeline. The company’s updates on payer and access groundwork, where applicable, will also be watched for early indicators of potential reimbursement pathways once regulatory milestones are met. Although none of these activities translate into immediate revenue, they increase visibility on resourcing needs, timeline expectations, and unit economics assumptions that will ultimately define the revenue trajectory in future periods.

Key stock-price drivers this quarter

Regulatory rhythm under the rolling review is the dominant near-term stock catalyst. Any color on the timing and completeness of submitted modules, the remaining components of the application, and next steps with the agency can influence sentiment and the perceived likelihood of a smooth pathway to submission and potential acceptance for review. Investors will also be focused on how the company is preparing for key pre-commercial steps, including manufacturing readiness and quality-systems build-out, since these are critical to any future approval and launch.

Clinical momentum continues to matter: the February 18, 2026 announcement that the second Phase 3 study met its primary endpoint strengthens the overall dataset, and any additional analyses or safety updates during the quarter could further shape expectations. On the operating side, the February 19, 2026 financing of 150.00 million US dollars helps fortify the balance sheet for ongoing development and pre-commercial activities; the quarter’s commentary around cash use and the projected runway will be an input to investor models and could moderate concerns about funding needs in the near term. Finally, execution on the April 21, 2026 Osmind collaboration is relevant for long-term scalability; near-term signals of clinic readiness frameworks and real-world protocol adoption may support confidence in the post-regulatory path.

Analyst Opinions

Bullish (8/8): All collected institutional opinions during the period are positive, with reiterations and initiations of Buy ratings and target prices clustered in the high-teens to low-20s, plus one high-end target. RBC Capital reaffirmed a Buy rating with a 21.00 US dollars target on March 24, 2026, pointing to continued confidence following late-stage clinical progress and a clearer regulatory runway under the rolling review. Oppenheimer maintained a Buy at 20.00 US dollars on March 24, 2026, citing the therapeutic profile and recent trial readouts that anchor expectations for the core program’s potential.

H.C. Wainwright reiterated a Buy with a 70.00 US dollars price target during the period, reflecting a view that clinical efficacy and the program’s potential market opportunity could support substantial equity value if regulatory steps proceed as planned. TD Cowen’s Ritu Baral maintained a Buy with a 29.00 US dollars target, highlighting robust Phase 3 efficacy and a favorable safety profile as the backbone of the bullish stance. Cantor Fitzgerald’s Joshua Schimmer maintained a Buy at 20.00 US dollars, aligning with peers on the value implications of clinical de-risking and regulatory momentum.

Two additional initiations reinforce consensus skew: Jefferies launched coverage with a Buy and an 18.00 US dollars target in early May 2026, and B. Riley initiated with a Buy and a 17.00 US dollars target in late April 2026, both following the string of program updates and regulatory progress. LifeSci Capital’s Francois Brisebois also maintained a Buy rating during the period, with targets cited at 19.00–23.00 US dollars in separate notes, reflecting incremental conviction after late-stage successes and the operational steps toward a potential filing.

The majority view centers on several themes. First, positive Phase 3 outcomes and alignment with regulators under a rolling review structure decrease clinical and regulatory uncertainty. Second, the February 19, 2026 financing removes some balance-sheet overhang and supports the resource needs of filing and commercialization groundwork. Third, the April 21, 2026 collaboration with Osmind is seen as practical progress toward defining how the therapy could be delivered at scale in real-world clinics—an important element for translating clinical efficacy into commercial execution. Collectively, these points underpin a constructive stance into the quarter, even as revenue remains at 0.00 million US dollars and EBIT loss is forecast at 47.06 million US dollars.

On estimates, the near-term numbers are straightforward given the pre-revenue status: consensus looks for EPS of -0.38, improving 19.19% year over year, and revenue flat at 0.00 million US dollars, while EBIT is expected to be -47.06 million US dollars, slightly worse year over year by 6.84%. Analysts broadly emphasize that the magnitude and cadence of operating losses are secondary to the timeline and clarity of regulatory steps, and to the readiness of the care-delivery footprint being built in parallel with the filing process. Upside or downside surprises this quarter, therefore, are likely to stem from qualitative disclosures—clarity on submission timing under the rolling review, any incremental clinical or safety analyses, indications of manufacturing and quality progress, or updates on clinic enablement—rather than variance in the headline P&L.

Given the unanimous bullish skew in the collected opinions for the period, the dominant institutional view heading into May 13, 2026 Pre-Market is that the company remains on a constructive path defined by late-stage efficacy readouts, tangible regulatory engagement, expanded coverage from additional banks, and a fortified funding position. While investors will not be focused on revenue this quarter, they will be parsing the update for markers that the regulatory dossier is progressing on schedule and that early commercialization building blocks are taking shape in clinics—both of which feature prominently in the majority of analyst models and narratives for the name.